Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation
|
|
- Ashley James
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2008, p Vol. 52, No /08/$ doi: /aac Copyright 2008, American Society for Microbiology. All Rights Reserved. Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation Thomas P. Lodise, Jr., 1,2 * Mark Gotfried, 3 Steven Barriere, 4 and George L. Drusano 2 Albany College of Pharmacy 1 and Ordway Research Institute, 2 Albany, New York; University of Arizona, Pulmonary Associates, Phoenix, Arizona 3 ; and Theravance, Inc., South San Francisco, California 4 Received 22 August 2007/Returned for modification 8 November 2007/Accepted 13 April 2008 Telavancin is an investigational bactericidal lipoglycopeptide with a multifunctional mechanism of action, as demonstrated against methicillin-resistant Staphylococcus aureus. While the plasma pharmacokinetics have been described, the extent of the penetration of the drug into the lung, measured by the epithelial lining fluid (ELF), remains unknown. Population modeling and Monte Carlo simulation were employed to estimate the penetration of telavancin into ELF. Plasma and ELF pharmacokinetic data were obtained from 20 healthy volunteers, and the pharmacokinetic samples were assayed by a validated liquid chromatography-tandem mass spectrometry technique. Concentration-time profiles in plasma and ELF were simultaneously modeled using a three-compartment model with zero-order infusion and first-order elimination and transfer. The model parameters were identified in a population pharmacokinetic analysis (BigNPAG). Monte Carlo simulation of 9,999 subjects was performed to calculate the ELF/plasma penetration ratios by estimating the area under the concentration-time curve (AUC) for the drug in ELF (AUC ELF ) and for the free drug in plasma (free AUC plasma ) from zero to infinity after a single dose. After the Bayesian step, the overall fits of the model to the data were good, and plots of predicted versus observed concentrations in plasma and ELF showed slopes and intercepts very close to the ideal values of 1.0 and 0.0, respectively. The median AUC ELF /free AUC plasma penetration ratio was 0.73, and the 25th and 75th percentile value ratios were 0.43 and 1.24, respectively. In uninfected lung tissue, the median AUC ELF is approximately 75% of the free AUC plasma. Staphylococcus aureus is the most frequent cause of health care-associated pneumonia in the United States, leading to considerable morbidity and mortality (10, 26). Treatment of S. aureus infections has been complicated by the emergence of S. aureus isolates expressing resistance to methicillin (5, 16, 22, 24). Infections caused by methicillin-resistant S. aureus (MRSA) account for 50% of all S. aureus strains isolated in many institutions. The increasing incidence of cross-resistant MRSA strains is further complicating treatment decisions (5, 16, 22, 24). Against this background of multidrug resistance, vancomycin has emerged as the drug of choice against MRSA. Despite its favorable susceptibility profile against MRSA, several reports within the past 10 years have described MRSA strains with intermediate susceptibility or high-level resistance to vancomycin, and some also question vancomycin s reduced activity against MRSA strains with MICs at the high end of the susceptible range (2, 3, 20, 28, 31). Telavancin, an investigational bactericidal lipoglycopeptide antibiotic, has been shown to have multifunctional mechanisms of action against MRSA (14, 15, 18). While the plasma pharmacokinetics have been described (29, 30), the ability of telavancin to penetrate and concentrate in the lung, as measured by the epithelial lining fluid (ELF), has not been fully elucidated. This study describes the population pharmacokinetics of telavancin in the plasma and ELF in healthy volunteers * Corresponding author. Mailing address: Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY Phone: (518) Fax: (518) lodiset@acp.edu. Published ahead of print on 21 April through nonparametric population pharmacokinetic modeling and Monte Carlo simulation. These analyses estimate the range of ELF penetration likely to be observed in this population (a surrogate for clinical practice), as measured by the ratio of the area under the concentration-time curve (AUC) for the drug in ELF to the AUC for the free drug in plasma (AUC ELF /free AUC plasma ratio). (This research was presented in part as a poster at the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 2005 [T. P. Lodise, L. Ma, M. Gotfried, S. Barriere, and G. L. Drusano, abstr. 526].) MATERIALS AND METHODS Patient population. Plasma and ELF concentration-time data for telavancin were obtained from a phase I, open-label, single-arm, multiple-dose, singlecenter study of 20 healthy Caucasian volunteers (12). All subjects received 10 mg of telavancin/kg of body weight intravenously as a 60-min infusion once daily for three consecutive days. Plasma samples for telavancin concentrations were collected preinfusion on days 1 and 3 and at 1, 2, 4, 6, 8, 12, and 24 h after completion of the day 3 infusion. Bronchoscopy samples for telavancin concentrations were collected on day 3 at 4, 8, 12, or 24 h following initiation of the study infusion. Each subject had a single bronchoscopy, and five subjects were nonrandomly assigned to be sampled at each bronchoscopy sampling time. Concentrations in plasma and ELF were assayed using a validated liquid chromatography-tandem mass spectrometry technique, with ELF volume determined by using urea as an endogenous marker (12). Population pharmacokinetic modeling. All data were analyzed in a population pharmacokinetic model using the big nonparametric adaptive grid (BigNPAG) with adaptive program of Leary, Jelliffe, Schumitzky, and Van Guilder (19). The pharmacokinetic model was parameterized as a three-compartment model with zero-order infusion into the central compartment. A three-compartment model with zero-order infusion was selected based on Akaike s information criterion and rule of parsimony (32). Elimination from the central compartment 2300
2 VOL. 52, 2008 PENETRATION OF TELAVANCIN INTO EPITHELIAL LINING FLUID 2301 TABLE 1. Telavancin population pharmacokinetic parameter estimates obtained by BigNPAG Parameter a Mean (SD) V C (liters) (0.57) CL (liters/h) (0.16) K 12 (h 1 ) (3.06) K 21 (h 1 ) (2.71) K 13 (h 1 ) (5.87) K 31 (h 1 ) (2.14) V ELF (liters) (19.60) a V C is a scalar and is the apparent volume of the central compartment. and all intercompartmental distribution processes were modeled as first-order processes. The general differential equations for the model are as follows: dx 1 /dt R t CL/V K 12 K 13 X 1 K 21 X 2 K 31 X 3 dx 2 /dt K 12 X 1 K 21 X 2 dx 3 /dt K 13 X 1 K 31 X 3 where X(1) is the amount of drug in the central compartment (in milligrams), X(2) is the amount of drug in the peripheral compartment (in milligrams), X(3) is the amount of drug in the ELF compartment (in milligrams), CL is clearance from the central compartment (in liters per hour), K 12, K 21, K 13, and K 31 are first-order intercompartmental transfer rate constants (in hour 1 ), V is a scalar and represents the volume of the central compartment (in liters), and R(t) is the time-delimited zero-order rate of drug input (piecewise input function) into the central compartment (in milligrams per hour). V ELF, a scalar term that represents the apparent volume of ELF, is not included in the equations. The inverse of the estimated assay variance was used as the first estimate for weighting in the pharmacokinetic modeling. Weighting was accomplished by making the assumption that total observation variance was proportional to assay variance. Assay variance was determined on a between-day basis. When convergence was attained, Bayesian estimates for each patient were obtained using the BigNPAG population-of-one utility. The mean, median, and modal values were employed as measures of central tendency for the population parameter estimates and were evaluated in the Bayesian analysis. Scatter plots were examined for individual patients and for the population as a whole. Goodness of fit was assessed by regression with an observed-predicted plot, coefficients of determination, and log-likelihood values. Predictive performance evaluation was based on weighted mean error and the bias-adjusted weighted mean-squared error. Monte Carlo simulation. The mean parameter vector and covariance matrix from the population pharmacokinetic model were embedded in Subroutine PRIOR of D Argenio and Schumitzky s ADAPT II software package (4). The population simulation without process noise option was employed. A Monte Carlo simulation with 9,999 subjects was performed and was used to calculate the mean and median ratios of ELF penetration to plasma penetration by estimating the AUC ELF and free or unbound AUC plasma from zero to infinity (AUC ELF,0- and free AUC plasma,0-, respectively) after a single simulated 750-mg dose and computing the ratio. Specifically, the AUCs in both ELF and plasma were calculated by integrating the concentration-time profile in each compartment from time zero (start of administration) to hour 2,000 post-start of administration. We integrated the profiles from time zero to hour 2,000 in order to approximate the AUC from zero to infinity (AUC 0- ). Given that the half-life of telavancin is 10 h, 2,000 h represents more than 200 telavancin half-lives and captures 99.9% of the cumulative exposure. The AUC ELF /free AUC plasma penetration ratio derived from the mean parameter vector from the population model was also calculated. Both normal and lognormal distributions were evaluated, and these were determined based on their abilities to recreate the mean parameter vector and corresponding standard deviations from the population model. The plasma pharmacokinetic data were adjusted for 90% protein binding (Theravance, Inc., internal report) to reflect unbound or free drug concentrations in the data analysis. The 90% protein binding value used for the analysis is lower than the published protein binding value of 93%, which is based on an early [ 3 H]telavancin study (29). More recent studies have used 14 C-radiolabeled telavancin of higher purity and have revealed protein (human plasma and albumin) binding to be approximately 88%; these data will be published in the near future (Theravance, Inc., internal report). To be conservative, we used 90% for the analysis. The ELF pharmacokinetic data were not adjusted for protein binding, because the protein binding of telavancin in ELF is currently unknown. Systat for Windows (version 10.2) was used for all data transformations. RESULTS The population parameter estimates identified by BigNPAG for the pharmacokinetic model are displayed in Table 1. Using the population mean parameter values as the measure of central tendency, the overall fit of the model to the data was good and the observed-predicted plots for plasma and ELF after the Bayesian step were highly acceptable. For plasma, the r 2 was and the observed-predicted plot showed a best-fit regression line of observed (1.008 predicted) (Fig. 1A). For ELF, the r 2 was and the observed-predicted plot showed a best-fit regression line of observed ( predicted) (Fig. 1B). A 9,999-subject Monte Carlo simulation was performed, and lognormal distributions were selected based on their abilities to recapitulate the original mean parameter values and corresponding standard deviations. The distributions of AUC ELF,0- and free AUC plasma,0- are shown in Fig. 2 and 3, respectively. FIG. 1. Observed versus predicted plots for plasma (A) and ELF (B). All values are in milligrams per liter.
3 2302 LODISE ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 2. Distribution of the ELF AUC 0- (in milligrams per hour per liter) for a Monte Carlo simulation (9,999 subjects) of a single 750-mg dose. Greater variability in AUCs was observed in ELF than in plasma. The mean (standard deviation) AUC ELF,0- and free AUC plasma,0- were (73.23) mg h/liter and (12.52) mg h/liter, respectively. The median (25th and 75th percentile values) AUC ELF,0- and free AUC plasma,0- were (30.90 and 92.43) mg h/liter and (65.03 and 82.02) mg h/liter, respectively. The distribution of AUC ELF,0- /free AUC plasma,0- penetration ratios is shown in Fig. 4. The mean AUC ELF /free AUC plasma penetration ratio standard deviation was The median AUC ELF /free AUC plasma penetration ratio was 0.73, and the 25th and 75th percentile value ratios were 0.43 and 1.24, respectively. The average value for the Monte Carlo simulation is skewed because of outliers, as is evident when one examines the AUC ELF,0- distribution (Fig. 2), the median penetration ratio of 0.73, the mean ratio of 1.01, and the large standard deviation of The AUC ELF /AUC plasma penetration ratio derived from the mean parameter vector from the population model was 0.66 and further reflects the influence of outliers on the mean penetration ratio from the Monte Carlo simulation. DISCUSSION Telavancin is an investigational lipoglycopeptide antibiotic with bactericidal activity against MRSA (14, 18) and is a potential treatment for hospital-acquired pneumonia. Therefore, FIG. 3. Distribution of the free plasma AUC 0- (in milligrams per hour per liter) for a Monte Carlo simulation (9,999 subjects) of a single 750-mg dose. FIG. 4. Distribution of AUC ELF /free AUC plasma penetration ratios. it is important to examine the ability of telavancin to concentrate in the ELF relative to plasma. Since optimal treatment depends on delivery of the antibiotic to the site of infection, it is imperative to accurately estimate the drug s ability to penetrate the infected site and achieve sufficient concentrations. For extracellular respiratory tract pathogens such as S. aureus, determination of the drug concentration in ELF is the best estimate available for ascertaining the degree of drug exposure against these organisms (6 8). Population pharmacokinetic modeling and Monte Carlo simulation techniques were used to identify the range of ELF concentration-time profiles (exposures) relative to plasma concentration-time profiles that one would observe in a normal healthy Caucasian. Most often, analysis of ELF penetration data is limited to obtaining ratios of drug concentrations in ELF to drug concentrations determined simultaneously in plasma. Because the drug has to penetrate from plasma to ELF, these ratios will change as a function of time, as observed in this study. This phenomenon, known as system hysteresis, makes examination of single time point penetration ratios suboptimal, because the estimates of drug penetration will strongly depend on the sampling time. Population pharmacokinetic modeling is able to overcome this limitation because of its ability to estimate population pharmacokinetics and their associated dispersions for subjects with minimal sampling times. Once the population pharmacokinetics are estimated, Monte Carlo simulation can be performed to estimate the ability of a drug to penetrate the site of infection and to characterize its AUC at that site. The mean AUC ELF /free AUC plasma ratios indicate that telavancin penetrates reasonably well into ELF compared to plasma. Specifically, the mean AUC ELF /free AUC plasma penetration ratio standard deviation was , and the median AUC ELF /free AUC plasma penetration ratio was 0.73 (25th and 75th percentile value ratios, 0.43 and 1.24, respectively). When one considers that the plasma protein binding of telavancin is approximately 90%, the total AUC for the drug in ELF approximates the AUC for the free drug in plasma. We employed estimated concentrations of the free drug in plasma for the penetration analysis because there are considerable data that demonstrate that protein binding has an adverse impact on microbiological outcomes and that only free or unbound drug is microbiologically active (1, 21). It should be
4 VOL. 52, 2008 PENETRATION OF TELAVANCIN INTO EPITHELIAL LINING FLUID 2303 noted, however, that there is evidence that telavancin operates, at least in part, through a membrane effect that is less impacted by the degree of protein binding (13). Total drug concentration was studied in ELF because the influence of protein binding in ELF has not yet been studied for telavancin or any other antibiotic, to our knowledge. Furthermore, previous studies suggest that most of the drug recovered in ELF will most likely be active as long as binding to tissue components is not appreciable (23, 25). Further study is needed to delineate the influence of protein binding in ELF. It is difficult to formally compare ELF penetration between telavancin and vancomycin; we are unaware of any randomized, crossover pharmacokinetic study that has employed population modeling and Monte Carlo simulation to compare the AUC ELF /free AUC plasma ratios of telavancin and vancomycin. The best vancomycin ELF penetration is derived from a study by G. L. Drusano et al. that used population modeling to estimate the penetration of vancomycin into the ELF of healthy subjects (9). In this study, the AUC ELF /free AUC plasma ratio for vancomycin was ca For hospitalized patients, the best vancomycin ELF penetration data come from a study that evaluated the entry of vancomycin into the ELF of critically ill patients (17). In this study, concentrations of vancomycin in plasma and ELF were collected simultaneously at various times for mechanically ventilated patients who received at least 5 days of vancomycin treatment. Assuming that vancomycin is 50% protein bound (27), the mean (standard deviation) and median (25th and 75th percentile values) ELF/free plasma concentration ratios were 0.38 (0.19) and 0.39 (0.26 and 0.48), respectively. In a similar study that evaluated the pulmonary disposition of vancomycin in critically ill patients 24 h after the onset of treatment (just before the next planned infusion of vancomycin), the average ratio of the penetration of vancomycin into ELF to the penetration of free vancomycin into plasma was only 0.14, and 6 of the 10 patients had no detectable vancomycin in their ELF (11). Further study of the AUC ELF / free AUC plasma ratios for both telavancin and vancomycin by population modeling and Monte Carlo simulation techniques is still needed, especially among hospitalized patients, but it may be inferred from these data that telavancin has a higher ELF/free plasma ratio than vancomycin. Of course, given that no randomized, crossover pharmacokinetic trial has been performed to date, overinterpretation of these data should be avoided. In summary, telavancin is an investigational lipoglycopeptide antibiotic that is being evaluated in phase III clinical trials for hospital-acquired pneumonia. Since antibiotic delivery to the site of infection is imperative for optimal therapy, we used population pharmacokinetic modeling and Monte Carlo simulation to characterize the penetration of telavancin into ELF relative to plasma. Overall, the results indicate that telavancin penetrates reasonably well into ELF compared to plasma, as defined by the mean AUC ELF /free AUC plasma ratio in normal healthy volunteers. ACKNOWLEDGMENTS This study was supported by a grant from Theravance, Inc. T.P.L. was the principal investigator for this grant. Theravance only provided support to complete the project and was not involved in the following: design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation of the manuscript. Theravance reviewed the final manuscript. No other conflicts of interest exist for any of the authors. REFERENCES 1. Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano Human serum 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40: Centers for Disease Control and Prevention Staphylococcus aureus resistant to vancomycin United States, MMWR Morb. Mortal. Wkly. Rep. 51: Centers for Disease Control and Prevention Vancomycin-resistant Staphylococcus aureus Pennsylvania, MMWR Morb. Mortal. Wkly. Rep. 51: D Argenio, D. Z., and A. Schumitzky ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles. 5. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, and M. Beach Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, Clin. Infect. Dis. 32(Suppl. 2):S114 S Drusano, G. L Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nat. Rev. Microbiol. 2: Drusano, G. L Pharmacokinetics and pharmacodynamics of antimicrobials. Clin. Infect. Dis. 45(Suppl. 1):S89 S Drusano, G. L., S. L. Preston, M. H. Gotfried, L. H. Danziger, and K. A. Rodvold Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46: Drusano, G. L., C. M. Rubino, P. G. Ambrose, S. M. Bhavnani, A. Forrest, A. Louie, M. Gotfried, and K. A. Rodvold Penetration of vancomycin into epithelial lining fluid, abstr.a-11. In Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC. 10. Fridkin, S. K Increasing prevalence of antimicrobial resistance in intensive care units. Crit. Care Med. 29:N64 N Georges, H., O. Leroy, S. Alfandari, B. Guery, M. Roussel-Delvallez, C. Dhennain, and G. Beaucaire Pulmonary disposition of vancomycin in critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 16: Gotfried, M. H., J. P. Shaw, B. M. Benton, K. M. Krause, M. R. Goldberg, M. M. Kitt, and S. L. Barriere Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob. Agents Chemother. 52: Hegde, S. S., N. Reyes, T. Wiens, N. Vanasse, R. Skinner, J. McCullough, K. Kaniga, J. Pace, R. Thomas, J. P. Shaw, G. Obedencio, and J. K. Judice Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48: Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: Kanafani, Z. A Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev. Anti-Infect. Ther. 4: Klevens, R. M., J. R. Edwards, F. C. Tenover, L. C. McDonald, T. Horan, and R. Gaynes Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, Clin. Infect. Dis. 42: Lamer, C., V. de Beco, P. Soler, S. Calvat, J. Y. Fagon, M. C. Dombret, R. Farinotti, J. Chastre, and C. Gibert Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. 37: Laohavaleeson, S., J. L. Kuti, and D. P. Nicolau Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin. Investig. Drugs 16: Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder An adaptive grid, nonparametric approach to pharmacokinetic and dynamic (PK/PD) models, p In Proceedings, Fourteenth IEEE Symposium on Computer-Based Medical Systems, July IEEE Computer Society, Bethesda, MD. 20. Menichetti, F Current and emerging serious Gram-positive infections. Clin. Microbiol. Infect. 11(Suppl. 3): Merrikin, D. J., J. Briant, and G. N. Rolinson Effect of protein binding on antibiotic activity in vivo. J. Antimicrob. Chemother. 11:
5 2304 LODISE ET AL. ANTIMICROB. AGENTS CHEMOTHER. 22. National Nosocomial Infections Surveillance (NNIS) System National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October Am. J. Infect. Control 32: Nix, D. E., S. D. Goodwin, C. A. Peloquin, D. L. Rotella, and J. J. Schentag Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob. Agents Chemother. 35: Noskin, G. A., R. J. Rubin, J. J. Schentag, J. Kluytmans, E. C. Hedblom, M. Smulders, E. Lapetina, and E. Gemmen The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch. Intern. Med. 165: Pennington, J. E Penetration of antibiotics into respiratory secretions. Rev. Infect. Dis. 3: Richards, M. J., J. R. Edwards, D. H. Culver, R. P. Gaynes, et al Nosocomial infections in medical intensive care units in the United States. Crit. Care Med. 27: Rybak, M. J The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(Suppl. 1):S35 S Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42: Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49: Sun, H. K., K. Duchin, C. H. Nightingale, J. P. Shaw, J. Seroogy, and D. P. Nicolau Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50: Whitener, C. J., S. Y. Park, F. A. Browne, L. J. Parent, K. Julian, B. Bozdogan, P. C. Appelbaum, J. Chaitram, L. M. Weigel, J. Jernigan, L. K. McDougal, F. C. Tenover, and S. K. Fridkin Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin. Infect. Dis. 38: Yamaoka, K., T. Nakagawa, and T. Uno Application of Akaike s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6: Downloaded from on September 13, 2018 by guest
MRSA Micro Scan Pos Combo 6J DADE BEHRING VCM
PKPD MRSA 1 1 2 1 1 2 17 1 26 17 3 16 vancomycinvcm methicillin-resistant Staphylococcus aureusmrsa 31 pharmacokineticpkparameter retrospective VCM 21 10 PK parameter Mann- Whitney U-test Cmax 37.1 µ gml29.942
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More informationRunning title: Comparative Efficacy of Telavancin and Vancomycin. Key words: human simulated, vancomycin intermediate Staphylococcus aureus,
AAC Accepts, published online ahead of print on 13 September 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00062-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationD DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.
Journal of Pharmacy and Pharmacology 2 (2014) 713-721 doi: 10.17265/2328-2150/2014.12.004 D DAVID PUBLISHING Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within
More informationPulmonary Disposition of Tedizolid Following Once-Daily Oral 200 mg Tedizolid. Phosphate in Healthy Adult Volunteers
AAC Accepts, published online ahead of print on 13 February 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05354-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Version
More information%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.
THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 159( 55 ) ( 2 15 ) %T MIC MIC 2002 30%T MIC 50%T MIC 1000 mg 3 3 /day Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration
More informationMONTE CARLO SIMULATION & PK-PD TARGET ATTAINMENT ANALYSIS:
MONTE CARLO SIMULATION & PK-PD TARGET ATTAINMENT ANALYSIS: Application to Estimation of MIC Breakpoints Paul G. Ambrose, Pharm.D. Director, Division of Infectious Diseases, Cognigen Corporation; Adjunct
More informationPopulation Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2003, p. 548 553 Vol. 47, No. 2 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.2.548 553.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationNORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR GENERAL PRACTICE
APRIL 2011 PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Methicillin-Resistant Staphylococcus 2
More informationA Randomized Phase 2 Trial to Evaluate the Clinical Efficacy of Two High Tigecycline
AAC Accepts, published online ahead of print on 28 January 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01232-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 A Randomized
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationNephrotoxicity. Pros and Cons of the article: Relationship between Initial Vancomycin
Pros and Cons of the article: Relationship between Initial Vancomycin Nephrotoxicity among Hospitalized Patients Diane M. Cappelletty, Pharm.D. Associate Professor Pharmacy Practice The University of Toledo
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationLong Half-life Drugs in Infectious Diseases: Implications and Complications
Long Half-life Drugs in Infectious Diseases: Implications and Complications In Session: Drugs That Just Won t Leave: From Stars of the Party to Unwelcome Guests Annual Meeting of the AAPS, San Diego, California
More informationBack to the Future: Using Aminoglycosides Again and How to Dose Them Optimally
INVITED ARTICLE ANTIMICROBIAL RESISTANCE George M. Eliopoulos, Section Editor Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally George L. Drusano, Paul G. Ambrose, Sujata M.
More informationAbsolute Bioavailability and Pharmacokinetics of Linezolid in Hospitalized Patients Given Enteral Feedings
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3676 3681 Vol. 49, No. 9 0066-4804/05/$08.00 0 doi:10.1128/aac.49.9.3676 3681.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationTHERAPEUTIC MONITORING OF VANCOMYCIN IN CLINICAL PRACTICE
THERAPEUTIC MONITORING OF VANCOMYCIN IN CLINICAL PRACTICE Hana Suchánková, Martina Machačová, Tereza Herodesová Department of Pharmacology, University Hospital Olomouc Introduction and objective: Routine
More informationASHP Therapeutic Position Statements 623
ASHP Therapeutic Position Statements 623 Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society
More informationRelationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2004, p. 2398 2402 Vol. 42, No. 6 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.6.2398 2402.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationDepartment of Pharmacy Services, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; 2
Pathogens 2015, 4, 599-605; doi:10.3390/pathogens4030599 Article OPEN ACCESS pathogens ISSN 2076-0817 www.mdpi.com/journal/pathogens Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for
More informationPD Targets for Various Infection Types: Stasis vs. 1-Log Kill vs. 2 Log Kill
PD Targets for Various Infection Types: Stasis vs. 1-Log Kill vs. 2 Log Kill G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation University of Florida To have insight into appropriate
More informationPharmacodynamics: the methods
Pharmacodynamics: the methods In vitro models Animal models Clinical studies Population studies With the support of Wallonie-Bruxelles-International 3B-1 Pharmacodynamics: the methods "un peu de tout "
More informationSuperhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia
Superhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia Brandon Dionne, PharmD, BCPS, AAHIVP Assistant Clinical Professor Northeastern University Seth Housman, PharmD, MPA Clinical Assistant
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationEstimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus
Estimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus Alison K Meagher, PharmD Cognigen Corporation 45 th ICAAC December 17, 2005 Julie Passarell, M.A. Cognigen
More informationJAC Computer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 63 68 JAC Computer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes M. J. Y. Bouvier
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationChallenges in Therapeutic Drug Monitoring:
Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationReceived 4 June 2010/Returned for modification 29 August 2010/Accepted 14 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 539 545 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.00763-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. In Silico
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationMupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010
Mupirocin Rationale for the EUCAST clinical breakpoints, version 1.0 6 th July 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationReceived 13 December 2010/Returned for modification 13 March 2011/Accepted 28 April 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3284 3294 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01733-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Population
More informationClinical Therapeutics/Volume 35, Number 6, 2013 Antimicrobial Stewardship
Clinical Therapeutics/Volume 35, Number 6, 2013 Antimicrobial Stewardship A Stewardship Program s Retrospective Evaluation of Vancomycin AUC 24 /MIC and Time to Microbiological Clearance in Patients with
More informationJohan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics
Exposure - Response Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics ACTVITY in vitro (MIC) CONCENTRATIONS in vivo (PK) DOSING regimen Other factors ANTMICROBIAL EFFICACY (Microbiological
More information/01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2001, p. 3468 3473 Vol. 45, No. 12 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.12.3468 3473.2001 Copyright 2001, American Society for Microbiology. All Rights
More informationLower respiratory tract infections are the second leading cause of morbidity and. crossm
EXPERIMENTAL THERAPEUTICS crossm In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model Alexander J. Lepak, a Miao Zhao, a,c Karen
More informationPharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2006, p. 3245 3249 Vol. 50, No. 10 0066-4804/06/$08.00 0 doi:10.1128/aac.00247-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Pharmacokinetics
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationIn vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates
AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationOptimizing Drug Exposure
Optimizing Drug Exposure All Patients Are Not Average Michael Neely, MD, MSc Associate Professor, Pediatrics Keck School of Medicine, University of Southern California Laboratory of Applied Pharmacokinetics
More informationQuinine Pharmacokinetics and Pharmacodynamics in Children with Malaria Caused by Plasmodium falciparum
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3658 3662 Vol. 49, No. 9 0066-4804/05/$08.00 0 doi:10.1128/aac.49.9.3658 3662.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationPharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation. Solution) in Cystic Fibrosis Subjects
4 1 2 3 5 6 7 8 9 AAC Accepts, published online ahead of print on 28 March 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01744-10 Copyright 2011, American Society for Microbiology and/or the Listed
More informationESCMID Online Lecture Library. by author
Disclosures Pk/Pd of antifungal drugs Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker Dosing should be such that the level of antmicrobial
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationComparison of Omadacycline and Tigecycline Pharmacokinetics in the. Plasma, Epithelial Lining Fluid, and Alveolar Cells in Healthy Adult Subjects
AAC Accepted Manuscript Posted Online 10 July 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.01135-17 Copyright 2017 Gotfried et al. This is an open-access article distributed under the terms of the
More informationClinical Therapeutics/Volume 29, Number 6, 2007
Clinical Therapeutics/Volume 29, Number 6, 2007 A Retrospective Analysis of Possible Renal Toxicity Associated with Vancomycin in Patients with Health Care Associated Methicillin-Resistant Staphylococcus
More informationOptimized Use of Vancomycin
E-Newsletter #1 Optimized Use of Vancomycin FROM THE EDITOR S DESK Methicillin-resistant Staphylococcus aureus (MRSA) is a serious concern for clinicians managing infectious diseases in the healthcare
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationPharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated
Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia* Emmanuel Boselli, MD; Dominique Breilh, PharmD, PhD; Thomas
More informationClinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
Clin Pharmacokinet (2018) 57:797 816 https://doi.org/10.1007/s40262-017-0623-4 REVIEW ARTICLE Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides Valentin
More informationTherapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus
Infect Dis Ther (2016) 5:81 87 DOI 10.1007/s40121-015-0100-z CASE REPORT Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus Yoshihiko Nakamura.
More informationGuidelines for Monitoring of Vancomycin Serum Concentrations in Adult Patients
Guidelines for Monitoring of Vancomycin Serum Concentrations in Adult Patients Guidelines developed by UWHC Department of Pharmacy Author: Cindy Gaston, RPh, PharmD Reviewed by: Antimicrobial Subcommittee,
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationPharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis Julie B Prahl, MD, PhD International Reference Laboratory of Mycobacteriology, Diagnostics and Infection Control
More informationActivity of antibiotics against intracellular S. aureus
Activity of antibiotics against intracellular S. aureus F. Van Bambeke Unité de Pharmacologie cellulaire et moléculaire Université catholique de Louvain Brussels, Belgium Disclosures Grants-in-aid from
More informationVancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1982, p. 575-58 66484/82/4575-6$2./ Vol. 21, No. 4 Vancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects ROBERT A. BLOUIN,1 LARRY A. BAUER,3* DELWYN
More informationDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Pharmacy Faculty, Siam University, Bangkok, Thailand
1 2 Article Type: Guest Ed Mistakes We Make in Dialysis 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 We underdose antibiotics in patients on CRRT Alexander R. Shaw Weerachai Chaijamorn Bruce A. Mueller 1 Ann
More informationHEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY
HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationReceived 4 December 2006/Returned for modification 8 March 2007/Accepted 9 June 2007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2007, p. 3049 3055 Vol. 51, No. 9 0066-4804/07/$08.00 0 doi:10.1128/aac.01522-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Pharmacokinetics
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationABSTRACT BRIEF REPORT. Alan J. Xiao. Luzelena Caro. Myra W. Popejoy. Jennifer A. Huntington. Ravina Kullar
Infect Dis Ther (2017) 6:137 148 DOI 10.1007/s40121-016-0143-9 BRIEF REPORT PK/PD Target Attainment With Ceftolozane/ Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function,
More informationDisclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past
Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.
More informationEMA Workshop Estimating the Probability of Target Attainment
EMA Workshop Estimating the Probability of Target Attainment G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation University of Florida Attainment We all tend to think problems
More informationReceived 24 August 2010/Returned for modification 7 November 2010/Accepted 7 February 2011
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1583 1587 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.01719-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Clinical and
More informationReceived 30 November 2008/Returned for modification 24 March 2009/Accepted 3 June 2009
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2009, p. 3894 3901 Vol. 53, No. 9 0066-4804/09/$08.00 0 doi:10.1128/aac.01585-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Pharmacodynamics
More informationAssessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines
Original Article Clinical Chemistry Ann Lab Med 2014;34:1-6 http://dx.doi.org/10.3343/alm.2014.34.1.1 ISSN 2234-3806 eissn 2234-3814 Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients
More informationThe Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
SUPPLEMENT ARTICLE The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin Michael J. Rybak Anti-Infective Research Laboratory, Department of Pharmacy Practice, College of Pharmacy and Health
More informationSkin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more)
Skin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more) Christian Eckmann Antibiotic Stewardship Expert ECDC Chief of Staff Department of General, Visceral and Thoracic Surgery Klinikum
More informationImpact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia
Journal of Microbiology, Immunology and Infection (2012) 45, 214e220 Available online at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE Impact of vancomycin MIC creep on patients
More informationVancomycin: A 50-something-yearold antibiotic we still don t understand
Current Drug Therapy CME CREDIT EDUCATIONAL OBJECTIVES: Readers will use vancomycin appropriately Amy Schilling, PharmD Department of Pharmacy, The University of Texas Medical Branch, Galveston Elizabeth
More informationOutpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry
doi: 10.1111/j.1742-1241.2008.01824.x ORIGINAL PAPER Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry W. J. Martone, K. C. Lindfield, D. E. Katz OnlineOpen: This
More informationTitle. Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): Issue Date Doc URL. Rights.
Title The Administration of Ciprofloxacin During Continuou Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): 243-245 Issue Date 2009-05 Doc URL http://hdl.handle.net/2115/43035
More informationThe Clinical Management of Hospital Acquired Pneumonia. NHS Ayrshire & Arran
The Clinical Management of Hospital Acquired Pneumonia Dr R G Masterton NHS Ayrshire & Arran What s new in HAP/VAP? Care bundles MRSA VAP Improving outcomes with current antimicrobial New antimicrobials
More informationSteven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 2063 2069 Vol. 54, No. 5 0066-4804/10/$12.00 doi:10.1128/aac.01569-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative
More informationTitle: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations
1 SUPPLEMENTARY MATERIALS 2 3 4 5 6 7 8 Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two Phase 2 clinical trials Authors: Radojka M. Savic,
More informationORIGINAL ARTICLE DOI: (e) ISSN Online: (p) ISSN Print: Anand Kumar Singh 1, Poonam Verma 2. Sciences, Dehradun
ORIGINAL ARTICLE CLINICAL ASSESSMENT OF NEPHROTOXICITY ASSOCIATED WITH VANCOMYCIN TROUGH CONCENTRATIONS DURING TREATMENT OF DEEP-SEATED INFECTIONS: A RETROSPECTIVE ANALYSIS Anand Kumar Singh 1, Poonam
More informationComparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given 0.5-h and 3-h intravenous infusions
AAC Accepts, published online ahead of print on 20 April 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01578-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationSCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past
Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated
More informationVancomycin MIC for Methicillin-Resistant Coagulase-Negative Staphylococcus. sp.: Evaluation of the Broth Microdilution and Etest Methods
JCM Accepts, published online ahead of print on 22 September 2010 J. Clin. Microbiol. doi:10.1128/jcm.01182-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationSimple Linear Regression the model, estimation and testing
Simple Linear Regression the model, estimation and testing Lecture No. 05 Example 1 A production manager has compared the dexterity test scores of five assembly-line employees with their hourly productivity.
More informationReceived 26 March 2008/Returned for modification 5 May 2008/Accepted 9 July 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2008, p. 2950 2954 Vol. 46, No. 9 0095-1137/08/$08.00 0 doi:10.1128/jcm.00582-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Characterization
More informationPharmacokinetic study of garenoxacin in severe renal failure patients
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 141 1 Pharmacokinetic study of garenoxacin in severe renal failure patients YUKA YAMAGISHI 1, 2, MAO HAGIHARA 2, YUKIHIRO HAMADA 2, YUKIHIRO KIMURA 3,
More informationPaul Beringer,* Amir Aminimanizani,* Timothy Synold, and Christy Scott
Therapeutic Drug Monitoring 24:315 321 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Development of Population Pharmacokinetic Models and Optimal Sampling Times for Ibuprofen Tablet and Suspension
More informationHuman Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2011, p. 4386 4393 Vol. 55, No. 9 0066-4804/11/$12.00 doi:10.1128/aac.00832-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Human
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More informationthe American Society of Health-System Pharmacists, the Infectious Diseases Society of
1 2 3 4 Therapeutic monitoring of vancomycin: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious
More informationIs the package insert correct? PK considerations
Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationVISA infections. Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis
VISA infections Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis jeanralph.zahar@aphp.fr H VISA and VISA infections Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis
More informationEfficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae Strains in a rabbit meningitis model.
AAC Accepts, published online ahead of print on 3 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00285-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 1 2 Efficacy
More informationComparisons between Antimicrobial Pharmacodynamic Indices and Bacterial Killing as Described by Using the Zhi Model
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1998, p. 1731 1737 Vol. 42, No. 7 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Comparisons between Antimicrobial
More informationTeicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients with Neutropenic Fever
Original Article DOI 10.3349/ymj.2011.52.4.616 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 52(4):616-623, 2011 Teicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients
More information